Generation Bio Co. (GBIO)
NASDAQ: GBIO
· Real-Time Price · USD
0.44
0.00 (0.00%)
At close: May 02, 2025, 3:59 PM
0.44
-0.14%
After-hours: May 02, 2025, 04:02 PM EDT
Company Description
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases.
The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina.
It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.
Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Generation Bio Co.
| Country | United States |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Dr. Cameron Geoffrey McDonough M.D. |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts United States | |
| Website | https://generationbio.com |
Stock Details
| Ticker Symbol | GBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001733294 |
| CUSIP Number | 37148K100 |
| ISIN Number | US37148K1007 |
| Employer ID | 81-4301281 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Geoffrey McDonough M.D. | President, Chief Executive Officer & Director |
| Kevin John Conway | Chief Financial Officer |
| Yalonda Howze J.D. | Chief Legal Officer & Secretary |
| Caitlin Cooper M.B.A. | Senior Vice President & Head of Business Development |
| Dr. Mark D. Angelino Ph.D. | Co-Founder |
| Dr. Robert Kotin Ph.D. | Co-Founder |
| Jasmin Tower | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Filing |
| Apr 23, 2025 | DEF 14A | Filing |
| Apr 17, 2025 | 4 | Filing |
| Apr 17, 2025 | 4 | Filing |
| Apr 17, 2025 | 4 | Filing |
| Apr 17, 2025 | 4 | Filing |
| Apr 17, 2025 | 4 | Filing |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |